Nasal decongestants for the common cold

Taverner, David; Latte, G. Jenny

doi:10.1002/14651858.cd001953.pub3

Cited by 73 publications

(16 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, this meta-analysis also reported a statistically significant, 24% reduction in nasal airway resistance with the use of a decongestant 93. A small increase in the risk of insomnia with pseudoephedrine compared with placebo was one of the few adverse events 93.…”

Section: Pharmacologic Therapy For Congestionmentioning

confidence: 77%

“…A Cochrane database meta-analysis assessed the efficacy of topical decongestants in reducing nasal congestion in adults suffering from the common cold, demonstrating a modest but statistically significant 6% decrease in patient-reported symptoms after a single dose of intranasal decongestant compared with placebo 93. In addition, this meta-analysis also reported a statistically significant, 24% reduction in nasal airway resistance with the use of a decongestant 93.…”

Section: Pharmacologic Therapy For Congestionmentioning

confidence: 90%

See 1 more Smart Citation

Treatment of congestion in upper respiratory diseases

Meltzer

Caballero²,

Fromer³

et al. 2010

IJGM

View full text Add to dashboard Cite

Congestion, as a symptom of upper respiratory tract diseases including seasonal and perennial allergic rhinitis, acute and chronic rhinosinusitis, and nasal polyposis, is principally caused by mucosal inflammation. Though effective pharmacotherapy options exist, no agent is universally efficacious; therapeutic decisions must account for individual patient preferences. Oral H1-antihistamines, though effective for the common symptoms of allergic rhinitis, have modest decongestant action, as do leukotriene receptor antagonists. Intranasal antihistamines appear to improve congestion better than oral forms. Topical decongestants reduce congestion associated with allergic rhinitis, but local adverse effects make them unsuitable for long-term use. Oral decongestants show some efficacy against congestion in allergic rhinitis and the common cold, and can be combined with oral antihistamines. Intranasal corticosteroids have broad anti-inflammatory activities, are the most potent long-term pharmacologic treatment of congestion associated with allergic rhinitis, and show some congestion relief in rhinosinusitis and nasal polyposis. Immunotherapy and surgery may be used in some cases refractory to pharmacotherapy. Steps in congestion management include (1) diagnosis of the cause(s), (2) patient education and monitoring, (3) avoidance of environmental triggers where possible, (4) pharmacotherapy, and (5) immunotherapy (for patients with allergic rhinitis) or surgery for patients whose condition is otherwise uncontrolled.

show abstract

Section: Pharmacologic Therapy For Congestionmentioning

confidence: 77%

Section: Pharmacologic Therapy For Congestionmentioning

confidence: 90%

Treatment of congestion in upper respiratory diseases

Meltzer

Caballero²,

Fromer³

et al. 2010

IJGM

View full text Add to dashboard Cite

show abstract

“…The effectiveness of topical and oral decongestants has been investigated in several trials, with three meta-analyses [37], [38], [39] and one systematic review [40] found.…”

Section: Types and Therapies Of Nasal Obstructionmentioning

confidence: 99%

Evidence and evidence gaps in therapies of nasal obstruction and rhinosinusitis

Rotter¹

2016

GMS Current Topics in Otorhinolaryngology - Head and Neck Surgery; 15:Doc06

View full text Add to dashboard Cite

“…The risk of rebound congestion with long-term intranasal decongestant use in adults is well documented 6,33,34 . Little research has been conducted on decongestant use in children, and a recent Cochrane Review concluded that they are not recommended in patients512 years 35 . In January 2008, the US Food and Drug Administration (FDA) strongly recommended that parents not use OTC cold and cough medicines, including antihistamines, antitussives, decongestants, and expectorants, in children 52 years, because of serious adverse effects -convulsions, rapid heart rates, decreased levels of consciousness 36 ; a review of these medications in children 2-11 years is underway 36 .…”

Section: Drug Classesmentioning

confidence: 99%